### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant Anders Gustavsson Serial No. : 10/531,412

Filing/371(c) Date : April 14, 2005 For : Method for the Synthesis of a Benzimidazole Compound

Examiner : Patricia L Morris

Group Art Unit : 1625

I hereby certify that this paper is being transmitted via the Electronic Filing System to the U S. Patent and Trademark Office on the date indicated below.

/Andrew Fessak/ February 2, 2007
Signature Date

## INFORMATION DISCLOSURE STATEMENT Under 37 C.F.R. \$1.97(c)

Mail Stop Amendment Assistant Commissioner for Patents Box 1450 Alexandria VA 22313-1450

Sir-

Applicant submits this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Favorable consideration of the document cited on the attached Form PTO/SB/08A is respectfully requested

#### Time of Transmittal of Information Disclosure Statement

This Information Disclosure Statement is being filled after the mailing date of the first.

Office Action on the merits but before the mailing date of either (1) a final action under §1.113 or (2) a notice of allowance under §1.311, whichever occurs first.

#### Statement or Fee

Accompanying this Information Disclosure Statement is

A. 

✓ a statement as specified in 37 C.F.R. §1.97 (e).

OR

B. 

the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00).

## STATEMENT OR FEE

Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Please charge any additional fee which may be required in connection with this communication to Deposit Account No. 23-1703.

Dated: February 2, 2007

Respectfully submitted,

/Andrew Fessak/
Reg. No. 48,528
Customer No. 007470
Direct Dial: (212) 819-8437

PTO/SB/SSA (08-03) (modified)
of Street Design 979 (2006 | ONG 9651-000) U.S. Parest and Tandemark Differ, U.S. DEPARTMENT OF COMMERCE. Raduction Act of 1995, no pain

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/531,412 Filing Date April 14, 2005 Anders Gustavsson Art Unit Patricia L. Morris

(Use as many sheets as necessary)					Examiner Name Patricia L. Morris			
Shret	1 of 1		1	Attorney Docket Number		1103326-0792		
			S. PATENT I		name of the same o			
Examiner	Cite	Document Number	Publication		Name of Patentee		Pages, Columns, Lines, Who	-
Initials	No.			MM-DD-YYYY Applicant of Cited Docume		ment	Relevant Passages/Figures App	
	1							
	-					-		-
						-		
	-							
	+		_			-		_
			_					-
		FOR	EIGN PATEN	T DO	CUMENTS			
Examiner initials	Cite	Foreign Patent Document	Publicate			or	Pages, Columns, Lines, Where	Τ
	No.	Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>2</sup> (st)	MM-DD	-YYYY	Applicant of Cited Document	Rei	Relevant Passages Or Relevant Figures Appear	13
	+	County Cost (Valida Valle Cost (g)	1		DOWNER	$\rightarrow$	rigates rippose	H
	+-					-		t
					1			t
								t
								_
					DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(a), volume-usiue number(a), publisher, city and/or country where published						
	1100	The Merck Index, 13th Ed. (2001), Merck & Co., Whitehouse Station, NJ, pages						
	1	305, 306, 369, 370, 1075, 1082, 1700, and 1718.						
	+-	Purification of Laborator				or C.	ionas (IICA) Inc	-
		New York, pages 157, 16		, Jui	5u. (2003), Eisevi	EL 30	ience (USA) mc.,	
	+	rew rork, pages 157, 10	33, and 370					
								_
	+							
	+							_
								_
Examiner Si	enature				Data Considered			

TOWERS, the first reasonable, which are not alone as sometimes with MTP 411. One further spin about in the a contribution of the spin and a contribution of